Teva Pharmaceutical Industries Ltd.'s results from a Phase II/III study ARM-TD (Aim to Reduce Movement in Tardive Dyskinesia) have been published in Neurology, the American Academy of Neurology's medical journal.
The study looked into the use of the drug deutetrabenazine (SD-809) in comparison to a placebo for the treatment of moderate-to-severe tardive dyskinesia, specifically in relation to the safety of the drug and its effect on the condition.
"Tardive dyskinesia is a chronic and debilitating condition that affect patients who are already suffering from significant primary psychiatric illnesses," Teva Chief Scientific Officer Michael Hayden said.
The study was led by Hubert Fernandez, a professor at the Center for Neurological Restoration at the Cleveland Clinic, and Karen Anderson, associate professor of Psychiatry & Neurology at Georgetown MedStar University Hospital.
With this new information from the study, treatments for patients with tardive dyskinesia may be more readily sought out.
Alerts Sign-up